


Sulfinpyrazone

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-B1271 | | |
| CAS No.: | 57-96-5 | | |
| Molecular Formula: | C ₂₃ H ₂₀ N ₂ O ₃ S | | |
| Molecular Weight: | 404.48 | | |
| Target: | Others | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (82.40 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

| Preparing Stock Solutions | Solvent Concentration | Mass | | |
|---------------------------|-----------------------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| | 1 mM | 2.4723 mL | 12.3616 mL | 24.7231 mL |
| | 5 mM | 0.4945 mL | 2.4723 mL | 4.9446 mL |
| | 10 mM | 0.2472 mL | 1.2362 mL | 2.4723 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (6.18 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects^{[1][2]}.

In Vitro

Sulfinpyrazone (G-28315) stimulates fibrinolytic activity^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In rats with kaolin-induced paw oedema, Sulfinpyrazone (G-28315) is able to restore the markedly prolonged euglobulin clot lysis time in an oral dose of 30 mg/kg. Beside these effects, Sulfinpyrazone protects rabbits from arachidonate-induced sudden death after a single oral dose of 10-30 mg/kg^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Margulies EH, White AM, Sherry S. Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. *Drugs*. 1980;20(3):179-197.
- [2]. Rüegg M. Antithrombotic effects of sulfinpyrazone in animals: influence on fibrinolysis and sodium arachidonate-induced pulmonary embolism. *Pharmacology*. 1976;14(6):522-536.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA